243 related articles for article (PubMed ID: 34242269)
1. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.
Marritt KL; Hildebrand KM; Hildebrand KN; Singla AK; Zemp FJ; Mahoney DJ; Jirik FR; Monument MJ
Front Immunol; 2022; 13():1087991. PubMed ID: 36700206
[TBL] [Abstract][Full Text] [Related]
3. A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
Buchakjian MR; Merritt NM; Moose DL; Dupuy AJ; Tanas MR; Henry MD
PLoS One; 2017; 12(8):e0183469. PubMed ID: 28841687
[TBL] [Abstract][Full Text] [Related]
4. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
6.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
7. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Wood GE; Meyer C; Petitprez F; D'Angelo SP
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
[TBL] [Abstract][Full Text] [Related]
9. Injury promotes sarcoma development in a genetically and temporally restricted manner.
Van Mater D; Xu E; Reddy A; Añó L; Sachdeva M; Huang W; Williams N; Ma Y; Love C; Happ L; Dave S; Kirsch DG
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333301
[TBL] [Abstract][Full Text] [Related]
10. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
Rivera-Reyes A; Ye S; E Marino G; Egolf S; E Ciotti G; Chor S; Liu Y; Posimo JM; Park PMC; Pak K; Babichev Y; Sostre-Colón J; Tameire F; Leli NM; Koumenis C; C Brady D; Mancuso A; Weber K; Gladdy R; Qi J; Eisinger-Mathason TSK
Cell Death Dis; 2018 Oct; 9(11):1108. PubMed ID: 30382078
[TBL] [Abstract][Full Text] [Related]
11. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.
Blum JM; Añó L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG
Cell Rep; 2013 Nov; 5(4):933-40. PubMed ID: 24239359
[TBL] [Abstract][Full Text] [Related]
12. Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation.
McKinnon T; Venier R; Dickson BC; Kabaroff L; Alkema M; Chen L; Shern JF; Yohe ME; Khan J; Gladdy RA
Oncotarget; 2015 Jun; 6(16):14220-32. PubMed ID: 25992772
[TBL] [Abstract][Full Text] [Related]
13. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization.
Brown JM; Patel R; Smith-Fry K; Ward M; Oliver T; Jones KB
Neoplasia; 2024 Feb; 48():100956. PubMed ID: 38199172
[TBL] [Abstract][Full Text] [Related]
15. Methods to generate genetically engineered mouse models of soft tissue sarcoma.
Dodd RD; Añó L; Blum JM; Li Z; Van Mater D; Kirsch DG
Methods Mol Biol; 2015; 1267():283-95. PubMed ID: 25636474
[TBL] [Abstract][Full Text] [Related]
16. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
17. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.
Hettmer S; Liu J; Miller CM; Lindsay MC; Sparks CA; Guertin DA; Bronson RT; Langenau DM; Wagers AJ
Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20002-7. PubMed ID: 22135462
[TBL] [Abstract][Full Text] [Related]
18. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
20. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
